Cercar
28/03/2025
Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC
Borque-Fernando, A, Alonso-Gordoa, T, Juan-Fita, MJ, Campos, FL, Pérez-Fentes, DA, Vilaseca, A, Agut, CM, Usán, P, Rey, PM. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. Future Oncology. 2025; 21(8)DOI:10.1080/14796694.2025.2468569. PMID:40029138. IF:2.600(Q3/6D).
01/03/2025
Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial
Piedra, A, Guinart-Cuadra, A, Recio, SM, Mulet, M, Atenza, CZ, Alejandre, J, Beltran, JS, Joaquín, AB, Sullivan, IG, López, JS, Casado, MDI, Aperribay, EA, Paz-Ares, L, Tain, PD, Vega, ALM, Callejo, A, Martos, JLL, Dominguez, M, Vidal, S, Majem, M. Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).
01/03/2025
TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C
Majem, M, O'Byrne, KJ, Lo Russo, G, Mueller, C, Triebel, F. TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).
01/03/2025
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis
Gillessen, S, Tombal, B, Turco, F, Choudhury, A, Rodriguez-Vida, A, Gallardo, E, Velho, PI, Nolè, F, Cruz, F, Loriot, Y, McDermott, R, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Polo, MH, da Trindade, KM, Preto, DD, Skoneczna, I, Lecouvet, F, Coens, C, Fournier, B, Saad, F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. EUROPEAN UROLOGY. 2025; 87(3)DOI:10.1016/j.eururo.2024.11.027. PMID:39827019. IF:25.200(Q1/1D).
01/03/2025
Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive stage small cell lung cancer
Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, MCM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive stage small cell lung cancer. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).
01/03/2025
First-line (1L) fulzerasib plus cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study
Majem, M, Gregorc, V, Lo Russo, G, Maio, M, Salvagni, S, Calderon, VG, Cao, MG, Contreras, SS, Koumarianou, A, Bearz, A, Caro, RB, Viteri, S, Sanmamed, MF, Zagouri, F, Bueno, MTM, Zhang, Y, Shan, Y, Zhu, H, Rosell, R. First-line (1L) fulzerasib plus cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).